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ventilation in COVID‑19 ARDS patients —
insights from the PRoVENT‑COVID study:
a national, multicenter, observational cohort
analysis
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Marcus J. Schultz4,9,10*, Pieter R. Tuinman3 and PRoVENT-COVID Study Collaborative Group* ‘PRactice of
VENTilation in COVID–19’

Abstract
Background: Increasing evidence indicates the potential benefits of restricted fluid management in critically ill
patients. Evidence lacks on the optimal fluid management strategy for invasively ventilated COVID-19 patients. We
hypothesized that the cumulative fluid balance would affect the successful liberation of invasive ventilation in COVID19 patients with acute respiratory distress syndrome (ARDS).
Methods: We analyzed data from the multicenter observational ‘PRactice of VENTilation in COVID-19 patients’ study.
Patients with confirmed COVID-19 and ARDS who required invasive ventilation during the first 3 months of the inter‑
national outbreak (March 1, 2020, to June 2020) across 22 hospitals in the Netherlands were included. The primary
outcome was successful liberation of invasive ventilation, modeled as a function of day 3 cumulative fluid balance
using Cox proportional hazards models, using the crude and the adjusted association. Sensitivity analyses without
missing data and modeling ARDS severity were performed.
Results: Among 650 patients, three groups were identified. Patients in the higher, intermediate, and lower groups
had a median cumulative fluid balance of 1.98 L (1.27–7.72 L), 0.78 L (0.26–1.27 L), and − 0.35 L (− 6.52–0.26 L), respec‑
tively. Higher day 3 cumulative fluid balance was significantly associated with a lower probability of successful ventila‑
tion liberation (adjusted hazard ratio 0.86, 95% CI 0.77–0.95, P = 0.0047). Sensitivity analyses showed similar results.
Conclusions: In a cohort of invasively ventilated patients with COVID-19 and ARDS, a higher cumulative fluid bal‑
ance was associated with a longer ventilation duration, indicating that restricted fluid management in these patients
may be beneficial.
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Background
Acute respiratory failure necessitating invasive ventilation is considered one of the leading causes of death in
patients with COVID-19 [1]. Intravenous fluid therapy
remains one of the cornerstones of resuscitation for
nearly all forms of shock. While early fluid resuscitation
is critical in managing shock, the accumulation of positive fluid balance has also been associated with worsening
acute respiratory distress syndrome (ARDS). A previous
study of non-COVID-19 patients with ARDS suggests
that a higher positive cumulative fluid balance is independently associated with mortality, longer ventilation
duration, and extended intensive care unit (ICU) stay
[2]. Based on this indirect evidence, consensus guidelines
during the early stages of the pandemic on the management of shock in patients with COVID-19 recommended
targeting a neutral fluid balance strategy [3].
Considerable evidence from observational studies, clinical trials, and systematic reviews indicates the
potential benefits of restricting fluid administration in
critically ill patients [4–7]. Excessive fluid administration may increase the risk of pulmonary complications
and the effects of edema in vital organs, causing injury

[8, 9]. On the other hand, a restrictive fluid strategy could
lead to extrapulmonary organ dysfunction consequent
to reduced cardiac output; however, more recent evidence suggests mixed results in critically ill patients [10,
11]. Therefore, the fluid balance being an adverse prognostic factor, yet also a potentially modifiable risk factor,
poses a unique dilemma in the management of critically
ill COVID-19 patients. Current evidence is insufficient
and constantly evolving to best address the optimal fluid
management strategy in invasively ventilated COVID-19
patients. Using the database of the multicenter observational ‘PRactice of VENTilation in COVID-19 patients’
(PRoVENT-COVID) study, we investigated cumulative
fluid balance in invasively ventilated COVID-19 and
ARDS patients and factors associated with a higher positive cumulative fluid balance. We aimed to test the association between the cumulative fluid balance during the
first 4 calendar days of invasive ventilation and successful
liberation of ventilation in these patients. We hypothesized that a higher cumulative fluid balance is independently associated with a lower probability of successful
liberation of invasive ventilation in COVID-19 ARDS
patients.
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Methods
Design

PRoVENT-COVID is an investigator-initiated national,
multicenter, observational cohort study that included
COVID-19 patients with acute respiratory failure requiring invasive ventilation in 22 hospitals in the Netherlands in the first 3 months of the international outbreak.
The study protocol was approved by the local institutional review board of Amsterdam University Medical
Center (location ‘AMC’) and registered at Clinicaltrials.gov (NCT04346342). The institutional review board
waived the requirement for written informed consent at
the participating sites. The original study protocol was
pre-published elsewhere [12]. The proposed plan and
statistical analysis of the current analysis were approved
by the Core Steering Committee and published with the
website of PRoVENT-COVID before data acquisition
[13]. The protocol was revised to address the unanticipated severely zero-inflated distribution of ventilatorfree days during the initial data acquisition (Additional
file 1: Fig. S1). This analysis adheres to the Strengthening
the Reporting of Observational Studies in Epidemiology
statement.
Selection criteria

Invasively ventilated adult patients who met the criteria for ARDS using the Berlin definition [14] and who
had real-time polymerase chain reaction confirmed
SARS-CoV-2 infection admitted to one of the participating ICUs were eligible for participation. The original PRoVENT-COVID study protocol had no exclusion
criteria; however, for the current analysis, we excluded
patients if they were not invasively ventilated beyond the
first 4 calendar days and patients who were transferred
within the first 4 days of ventilation from or to another
ICU that did not participate in the PRoVENT-COVID
study.
Exposure

The primary exposure of interest was the cumulative
fluid balance. Cumulative fluid balance was obtained as a
sum of daily fluid balance during the last 24-h, calculated
by total fluid input minus total fluid output on a certain
day of ICU admission for the first 4 calendar days of invasive ventilation. Insensible fluid loss such as perspiration
or evaporative water loss due to respiration was not routinely measured and not included in the cumulative fluid
balance calculation. Cumulative fluid balance from day 0
through day 1 was grouped as day 1, and the subsequent
days were labelled as day 2 and day 3. Cumulative fluid
balance during the first 4 calendar days is referred to
hereafter as cumulative fluid balance at day 3.
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Outcomes

The primary outcome was successful liberation from
invasive ventilation at 28 days. We chose this time frame
following previous ARDS trials typically because either
the subject died or extubated successfully by day 28 [15].
Secondary outcomes were acute kidney injury (according to a modified Kidney Disease Improving Global Outcomes definition) [16] and the need for renal replacement
therapy after day 7. This variable was collected as dichotomous variable (yes/no) during follow-up at day 7, 28,
and 90 [12]. Other secondary outcomes include duration
of invasive ventilation in survivors and non-survivors,
ICU and hospital length of stay in survivors and non-survivors, the incidence of tracheostomy in ICU, and 28-day
mortality.
Statistical analyses

Descriptive statistics were used to describe the study
population and fluid management parameters. Data are
presented as numbers and percentages for categorical
variables and as means and standard deviation or median
and interquartile range according to distribution. The
normality of the distributions of quantitative variables
was assessed by the Shapiro–Wilk test. Where appropriate, statistical variability is expressed by 95% confidence
intervals.
Using a mixed effects model, we first examined the
crude association between cumulative fluid balance and
successful liberation from ventilation at day 28 with successful liberation of ventilation as a dependent variable,
fluid balance as (fixed effect) as an independent variable,
and hospital as a random intercept effect. To examine
potential nonlinearity in the association, the cumulative fluid balance was entered as a restricted cubic spline
function with 3 knots distributed equally along the density. The complexity of the spline function was reduced
in a stepwise fashion until minimization of the Akaike
information criterion (AIC) (Additional file 1: Fig. S2).
The exposure (cumulative fluid balance at day 3) was
divided into tertiles to facilitate interpretation.
The association between cumulative fluid balance at
day 3 and the probability of successful liberation from
invasive ventilation was then adjusted for possible confounders by including these variables as (fixed effect)
covariates in the mixed effects model. Baseline physiological and laboratory variables (Day 0) were collected
within one hour of ICU arrival or one hour of initiation
of invasive ventilation, in accordance with the pre-published protocol [12]. The set of predefined adjustment
variables included the following: sex, age, body mass
index, serum creatinine, use of vasopressors (norepinephrine dose), tidal volume, arterial pH, positive endexpiratory pressure, partial pressure of oxygen to fraction
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inspired oxygen, dynamic respiratory system compliance
and arterial lactate, all measured on the day of intubation.
Conditional on the assumption that the data were missing at random and the severity illness scores were collected differently by hospitals, before imputation, the
percentage of missing data in the severity of illness scores
in the first 3 days were assessed and addressed by a multilevel multiple imputation method. We imputed 20 datasets using multiple imputation by chained equations [17].
No exposure (day 3 fluid balance) or outcomes (survival
and duration of ventilation) were imputed. All models
described in the ‘statistical analysis’ section were reproduced in the 20 databases after multiple imputations, and
the results were pooled. We considered statistical significance at P ≤ 0.05.
No formal statistical power calculation was conducted
before the study. The sample size was solely based on the
available data from the PRoVENT-COVID database.
Sensitivity analyses

To assess the robustness of the findings toward the
missing data and imputation method, we refit the main
regression model (i.e., the marginal effect of day 3 fluid
balance on the hazard of successful liberation from invasive ventilation) on cases with complete data only. To
retain the largest possible sample size, only covariates
that were significantly associated with the outcome in the
main model were included in the sensitivity model.
We also estimated the main effect of different classes of
ARDS severity (on the day of ICU admission) by including this variable in the adjusted mixed effects model.

Results
Patient population and characteristics

We identified 687 invasively ventilated COVID-19 and
ARDS patients admitted to ICUs between March 1, 2020,
and June 1, 2020. The study flowchart is summarized in
Fig. 1. Tables 1 and 2 describe the baseline, ventilation,
and ICU characteristics of our study participants. The
most prevalent comorbidities were hypertension and
diabetes.
Cumulative fluid balance distribution

The distribution of cumulative fluid balance at day 3 was
evaluated for the overall cohort (Additional file 1: Fig.
S3). Complete exposure (fluid balance) data were available for 676 subjects on day 0; 673 (99.5%) subjects on
day 1; 661 (97.7%) subjects on day 2; and 650 (96.1%)
subjects on day 3. Patients were divided into tertiles by
day 3 cumulative fluid balance: highest, intermediate,
and lowest tertile groups had a median cumulative fluid
balance of 1.98 L [range 1.27–7.72 L], 0.78 L [0.26–1.27
L], and − 0.35 L [− 6.52–0.26 L], respectively. Patients in
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the lower cumulative fluid balance group had a higher
prevalence of chronic hypertension and diabetes mellitus, whereas patients in the higher cumulative fluid balance group were noted to have worse baseline Simplified
Acute Physiology Score (Table 1).
Association of cumulative fluid balance with outcomes

The association between day 3 cumulative fluid balance
and the hazard of successful liberation from ventilation
was most parsimoniously characterized by a 0-spline
(linear) survival model. Models with 3-, 2-, or 1-knotrestricted cubic splines for cumulative fluid balance had
higher AICs (i.e., no better fit) (Additional file 1: Fig. S2).
The resulting association between cumulative fluid balance at day 3 and the probability of successful liberation
from invasive ventilation is shown in Fig. 2. In unadjusted
analysis, there was a significant association between
higher cumulative fluid balance at day 3 and a lower
probability of successful liberation from ventilation, with
a hazard ratio per liter fluid balance of 0.86 (95% CI 0.78–
0.96, P = 0.005). After adjusting for a predefined set of
possible confounding variables (listed in Additional file 1:
Table S1a), exposure to higher cumulative fluid balance
at day 3 remained significantly associated with lower
probability of successful liberation of invasive ventilation.
The adjusted hazard ratio for successful liberation from
invasive ventilation associated with each liter increase
in cumulative fluid balance was 0.86 (95% CI 0.77–0.95,
P = 0.0047). In the post hoc analysis, we assessed the
impact of imbalances of chronic baseline hypertension
and diabetes mellitus between the tertiles groups and
found no difference in the main effect estimate HR 0.83
(95%CI 0.73;0.94) compared to 0.86 (95% CI 0.78;0.96)
for the model without hypertension and diabetes (listed
in Additional file 1: Table S1b).
Secondary outcomes and sensitivity analysis

The secondary outcomes are summarized in Table 3.
Length of ICU stay, length of hospital stays, and duration of intubation were significantly shorter for surviving patients who were in the lower tertile of cumulative
fluid balance. Other outcomes did not differ significantly
between fluid balance tertiles.
Two sensitivity analyses were performed. First, the
robustness of our findings was assessed toward the
missing data and imputation method (Additional file 1:
Table S2). In the complete-cases-only model, the sample
size was reduced to 461 patients; the estimated association between day 3 cumulative fluid balance and successful liberation of invasive ventilation was similar to the
estimation with imputed data. The hazard ratio per liter
fluid balance was consistent with the primary analysis,
0.86 (95% CI 0.76–0.98, P = 0.0247).
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Fig. 1 Flowchart of the study

Second, the models were re-analyzed according to
ARDS severity on the ICU admission day, considering a
possible interaction between the severity of ARDS and
fluid balance. The interaction between ARDS severity
and day 3 cumulative fluid balance did not improve the
model fit (AIC of interaction model 4336 vs. 4335 for
reduced model), indicating that there was no significant
interaction between day 3 cumulative fluid balance and
ARDS severity on the association with successful liberation from invasive ventilation (Fig. 3).

Discussion
The main findings of this multicentric observational
study of COVID-19 and ARDS patients include the following: (1) A higher day 3 cumulative fluid balance was
associated with a lower probability of successful liberation from invasive ventilation by day 28; (2) these results
remained consistent even after adjustment for potential
predefined confounding factors and sensitivity analyses;
and (3) reduction in duration of invasive ventilation and
hospital and ICU length of stay was noted in patients
who had lower cumulative fluid balance.
Our results add to the growing evidence suggesting
the unfavorable effect of higher positive fluid balance

Ahuja et al. Critical Care

(2022) 26:157

Page 6 of 12

Table 1 Baseline characteristics of the included patient cohort
N (%)

Overall cohort

Lower

Intermediate

Higher

N = 650

215 (100.0)

220 (100.0)

215 (100.0)

P value

Demographic characteristics
Gender, male, N (%)

467 (71.8)

145 (67.8)

160 (72.7)

161 (74.9)

0.243

Age, years

66.00 [58.00, 73.00]

65.00 [57.00, 71.00]

66.50 [58.75, 72.25]

66.00 [59.00, 73.00]

0.289

Weight, kg

86.00 [78.00, 96.00]

85.00 [75.00, 94.60]

86.00 [79.00, 96.00]

88.40 [80.00, 98.30]

0.023

Height, cm

175.00 [169.00, 182.00]

175.00 [168.00, 180.00]

175.00 [169.00, 182.00]

176.00 [170.00, 182.50]

0.341

Body mass index, kg/m2

27.78 [25.72, 30.86]

27.44 [25.06, 30.48]

27.99 [25.71, 30.47]

28.34 [26.02, 31.62]

0.081

Comorbid conditions (%)
Comorbid. None

156 (24)

42 (19.6)

55 (25.0)

59 (27.4)

0.153

Hypertension

209 (32.2)

83 (38.8)

58 (26.4)

67 (31.2)

0.02

Heart failure

29 (4.5)

11 (5.1)

7 (3.2)

11 (5.1)

0.524

Diabetes mellitus

141 (21.7)

54 (25.2)

34 (15.5)

53 (24.7)

0.021

Chronic kidney disease

25 (3.8)

10 (4.7)

5 (2.3)

10 (4.7)

0.326

Liver cirrhosis

2 (0.3)

0 (0.0)

1 (0.5)

1 (0.5)

0.61

COPD

50 (7.7)

15 (7.0)

18 (8.2)

17 (7.9)

0.892

Hematological malignancy

10 (1.5)

3 (1.4)

4 (1.8)

3 (1.4)

0.919

Solid tumor malignancy

18 (2.8)

7 (3.3)

8 (3.6)

3 (1.4)

0.314

Neuromuscular disease

4 (0.6)

1 (0.5)

1 (0.5)

2 (0.9)

0.772

Immunosuppression use

10 (3.1)

7 (3.3)

6 (2.7)

7 (3.3)

0.932

Other comorbidities

315 (48.5)

108 (50.5)

108 (49.1)

99 (46.0)

0.644

Unknown comorbidities

2 (0.3)

1 (0.5)

1 (0.5)

0 (0.0)

0.608

Creatinine (µmol/L)

76.00 [61.00, 95.00]

74.00 [61.00, 93.00]

73.00 [57.50, 93.50]

79.00 [64.00, 103.25]

0.079

COPD chronic obstructive pulmonary disease
Data are shown as median [25th percentile, 75th percentile] or N (%). Non-normal values are displayed as median [25th percentile, 75th percentile], and those with
normal distribution are represented as mean (standard deviation)

on outcomes in critically ill patients [18–21]. However,
compared to these studies, there are also some notable
differences in our study. We specifically evaluated the
exposure of cumulative fluid balance in COVID-19 and
ARDS patients on the ventilation liberation irrespective
of prior spontaneous breathing trials. Cumulative fluid
balance was calculated from hospital admission until
day 3, whereas in other studies, it was calculated differently. Despite these differences, a signal of potential harm
with excessive cumulative fluid balance and weaning outcomes was consistently observed.
Evidence emanating from large trials of ARDS patients
has led to an overall practice change that resulted in
relatively less aggressive initial fluid management. In
2006, the Fluids and Catheters Treatment Trial reported
a causal effect between positive fluid balance and duration of ventilation in ARDS patients [5]. The authors
found that the conservative group had a shorter ventilation duration than the liberal-strategy group without
an increase in non-pulmonary organ failure. Another
study, performed by the ARDSnet, showed that negative cumulative fluid balance was significantly associated
with more ventilator-free days and lower mortality than

positive cumulative fluid balance [22]. A limitation of
using ‘ventilator-free days’ in these reports is that a more
frequently occurring component of the composite (such
as survival or duration of ventilation) presumably drives
the effect estimates and could influence the results, even
stronger when the components are oppositely affected
by the exposure [1, 15]. Our rationale for using ‘ventilator-free days’ was to compare our analysis to previously
conducted studies readily; one of the challenges was
disentangling the contribution of ‘zero-inflated distribution’ in ventilator-free days. However, it is possible that a
greater-than-expected number of non-survivors had died
within 24-h of initiation of ventilation, and this could
presumably drive the mean difference toward null. Or,
because of unknown factors, certain patients might not
have been able to present values other than zero. Nevertheless, we addressed it by restricting our primary outcome to only ‘successful ventilation liberation’ instead of
‘ventilator-free days’; however, our analysis suffered from
model selection bias.
Several mechanisms may explain the association of
higher early cumulative fluid balance and decreased odds
of ventilation liberation. Higher positive fluid balance
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Table 2 Ventilator and other ICU variables on admission and follow-up days
N (%)

Overall cohort

Lower

Intermediate

Higher

N = 650

215 (100.0)

220 (100.0)

215 (100.0)

P value

Day 0 variables (median [interquartile range])
Tidal volume (set)

410.50 [400.00, 480.00]

450.00 [400.00, 485.00]

400.00 [400.00, 420.00]

400.00 [380.00, 440.00]

0.271

Tidal volume (expired)

438.00 [387.00, 491.00]

434.50 [389.50, 476.25]

425.50 [379.25, 477.50]

450.00 [400.00, 508.00]

0.007

PEEP

12.00 [10.00, 15.00]

12.00 [10.00, 15.00]

12.00 [10.00, 14.00]

12.00 [10.00, 15.00]

0.125

Peak pressures

27.00 [24.00, 30.00]

28.00 [24.00, 31.00]

26.00 [24.00, 30.00]

27.00 [24.00, 30.00]

0.019

FiO2

0.70 [0.60, 0.85]

0.70 [0.60, 0.90]

0.65 [0.58, 0.80]

0.70 [0.60, 0.80]

0.105

pH

7.36 [7.30, 7.42]

7.36 [7.31, 7.41]

7.37 [7.31, 7.43]

7.36 [7.29, 7.41]

0.428

PaO2

10.88 [9.40, 13.00]

10.80 [9.50, 12.66]

10.80 [9.00, 13.15]

10.90 [9.50, 13.50]

0.682

PaO2/FiO2 ratio

123.00 [94.69, 165.66]

120.00 [96.59,153.92]

121.88 [92.78, 176.87]

130.03 [93.33, 171.25]

Dynamic compliance (Cdyn)

30.16 [24.16, 37.23]

28.62 [22.79, 34.62]

30.36 [23.79, 37.51]

31.38 [26.10, 40.77]

0.126
< 0.001

Lactate

1.20 [0.90, 1.50]

1.2 [0.97, 1.50]

1.20 [0.90, 1.50]

1.10 [0.90, 1.40]

0.084

SAPS

34.50 [28.75, 43.00]

32.00 [27.00, 38.00]

32.00 [26.50, 39.50]

38.00 [32.00, 45.50]

0.001

APACHE II

17.00 [12.00, 22.00]

16.00 [12.00, 22.00]

17.00 [11.50, 22.00]

16.00 [13.25, 19.75]

0.979

APACHE IV

56.95 [45.00, 69.00]

51.00 [43.00, 65.25]

56.50 [44.00, 65.00]

59.00 [46.00, 72.50]

0.083

SOFA

7.00 [6.00, 10.00]

7.00 [6.00, 10.00]

7.00 [6.00, 9.00]

8.00 [6.00, 9.00]

0.489

Creatinine (µmol/L)

73.00 [58.00, 93.00]

70.00 [57.00, 87.00]

73.00 [57.50, 93.50]

75.00 [63.00, 99.50]

0.055

Daily administered fluid (ml)

923.64 [298.50, 1744.25]

1131.50 [345.60, 1944.25]

784.05 [250.00, 1594.50]

875.00 [290.50, 1733.50]

0.034

Urine (ml)

780.00 [417.50, 1200.00]

780.00 [450.00, 1220.00]

825.00 [460.00, 1240.00]

725.00 [398.75, 1130.00]

0.152

Urine (ml/kg)

8.57 [4.71, 14.00]

9.07 [4.88, 14.67]

8.96 [5.11, 14.40]

7.76 [4.45, 12.69]

0.043

Ventilator-free days

3.00 [0.00, 11.00]

3.00 [0.00, 9.00]

4.00 [0.00, 11.25]

0.00 [0.00, 12.00]

0.286

Cumulative fluid balance day 661.50 [91.33, 1496.00]
0 (ml)

698.00 [− 34.00, 1598.00]

556.00 [37.50, 1283.10]

826.00 [212.00, 1762.00]

0.016

Number of patients on
norepinephrine

649 (99.8)

213 (99.5)

220 (100)

215 (100)

0.361

Norepinephrine dose, mg

0.45 [0.01, 3.37]

0.04 [0.01, 2.17]

0.78 [0.01, 3.40]

0.89 [0.01, 4.14]

0.005

Day 1 variables
SOFA

7.00 [6.00, 9.00]

7.00 [6.00, 9.00]

7.00 [5.25, 9.00]

7.00 [6.00, 9.00]

0.373

Creatinine (µmol/L)

84.00 [66.00, 118.00]

83.00 [66.00, 123.00]

80.00 [63.00, 111.00]

86.00 [68.00, 121.75]

0.171

Daily administered fluid (ml)

1670.50 [743.70, 2577.50] 1758.50 [848.05, 2588.50]

1435.50 [644.58, 2299.25] 1725.00 [750.00, 2851.35]

0.152

Urine (ml)

780.00 [417.50, 1200.00]

1125.00 [778.75, 1588.25]

1062.50 [805.00, 1446.25] 1202.02(697.48)

0.759

Urine (ml/kg)

8.57 [4.71, 14.00]

13.50 [8.92, 19.07]

12.62 [8.76, 17.38]

11.88 [8.40, 17.58]

Cumulative fluid balance (ml) 1621.00 [871.42, 2382.25] 1460.90 [649.70, 21,621.00] 1507.50 [824.12, 2116.50] 1918.00 [1173.35, 2867.45]
day 1

0.043
< 0.001

Number of patients on
norepinephrine

576 (88.6)

186 (86.9)

189 (85.9)

200 (93)

0.042

Norepinephrine, mg/24-h

11.20 [4.44, 49.96]

11.98 [3.60, 9216.00]

8.99 [3.46, 21.56]

12.21 [6.00, 41.40]

0.021

Day 2 variables
SOFA

7.00 [6.00, 10.00]

7.00 [6.00, 11.00]

7.00 [5.00, 9.00]

7.00 [6.00, 9.00]

0.232

Creatinine (µmol/L)

85.00 [66.00, 133.00]

86.00 [64.00, 131.00]

83.00 [63.75, 124.25]

87.00 [70.00, 143.00]

0.215

Daily administered fluid (ml)

1243.15 [460.90, 1997.75] 1288.50 [476.28, 1936.75]

1169.00 [411.67, 1822.57] 1230.00 [511.00, 2252.40]

Urine (ml)

1075.00 [774.00, 1503.25] 1407.50 [990.00, 2071.25]

1095.00 [833.75, 1437.75] 1121.19 (696.37)

Urine (ml/kg)

12.56 [8.74, 17.75]

17.19 [11.00, 24.66]

12.96 [8.97, 17.48]

11.00 [8.39, 16.16]

0.191
< 0.001
< 0.001

Cumulative fluid balance (ml) 1241.95 [548.75, 1979.75] 773.50 [0.25, 1398.75]
day 2

1157.00 [615.00, 1807.25] 1782.00 [1219.50, 2530.00]

< 0.001

Number of patients on
norepinephrine

551 (84.8)

167 (78)

187 (85)

196 (91.2)

0.001

Norepinephrine, mg/24-h

10.70 [4.12, 86.25]

12.40 [3.74, 9216.00]

7.92 [3.33, 26.64]

14.65 [5.11, 41.00]

0.017

Day 3 variables
SOFA

7.00 [6.00, 10.00]

7.00 [6.00, 11.00]

7.00 [5.00, 9.00]

7.00 [6.00, 9.00]

0.56

Creatinine (µmol/L)

84.00 [63.00, 140.00]

85.00 [62.00, 129.00]

79.50 [61.00, 127.50]

86.00 [68.00, 171.00]

0.07
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Table 2 (continued)
N (%)

Overall cohort

Lower

Intermediate

Higher

N = 650

215 (100.0)

220 (100.0)

215 (100.0)

977.98 [252.50, 1555.75]

650.70 [238.00, 1607.60]

1189.90 [504.00, 2160.00]

Daily administered fluid (ml)

956.40 [276.75, 1719.25]

Urine (ml)

1155.00 [830.00, 1640.00] 2112.50 [1511.25, 2735.00]

Urine (ml/kg)

13.33 [9.23, 19.22]

1280.00 [867.50, 1722.50] 1030.17 (641.13)

P value

< 0.001
< 0.001

24.04 [17.82, 32.83]

15.05 [10.43, 20.24]

11.23 [7.93, 14.72]

< 0.001

Cumulative fluid balance (ml) 780.00 [7.47, 1623.25]
day 3

− 344.75 [− 751.55, 1.72]

780.00 [499.72, 1013.75]

1988.00 [1638.30, 2397.00]

< 0.001

Number of patients on
norepinephrine

499 (76.8)

144 (67.3)

168 (76.4)

186 (86.5)

< 0.001

Norepinephrine, mg/24-h

9.90 [3.30, 91.78]

8.75 [2.70, 9216.00]

6.90 [2.45, 19.74]

13.75 [5.18, 58.13]

0.003

APACHE Acute Physiology Assessment and Chronic Health Evaluation, FiO2 fraction of inspired oxygen, PaO2 arterial partial pressure of oxygen, PEEP positive endexpiratory pressure, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
Data are shown as median [25th percentile, 75th percentile] or N (%). Non-normal values are displayed as median [25th percentile, 75th percentile], and those with
normal distribution are represented as mean (standard deviation)

Fig. 2 Survival and marginal effect plots. a Survival plots (unadjusted and adjusted) showing predicted probability of successful liberation of
invasive ventilation as a function of day 3 fluid balance—separated in tertiles. b Marginal effect (unadjusted and adjusted) of day 3 cumulative
fluid balance on the hazard of successful liberation from invasive ventilation after adjustment for predefined confounding variables. A higher day 3
cumulative fluid balance was associated with a lower hazard (i.e., a lower probability over time) of successful liberation
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Table 3 Patient-centered endpoints stratified by tertiles

Overall cohort, N = 650, N (%)

Lower

Intermediate

Higher
215 (100.0)

P value

215 (100.0)

220 (100.0)

Acute kidney injury

110 (52.1)

102 (46.6)

122 (56.7)

0.105

Requiring RRT

63 (29.4)

58 (26.4)

67 (31.2)

0.535

CVVH/CVVHDF

46 (21.5)

43 (19.5)

55 (25.6)

0.304

Hemodialysis

3 (1.4)

7 (3.2)

7 (3.3)

0.395

Peritoneal dialysis
28-day mortality
Duration of intubation at 28 days
Survivors
Non-survivors
Tracheostomy incidence in ICU
Intensive care unit length of stay
Survivors
Non-survivors
Hospital length of stay

0 (0.0)

0(0.0)

1 (0.5)

0.364

62 (29.0)

61 (27.7)

78 (36.3)

0.116

8.00 [4.00, 16.00]

11.00 [5.00, 21.00]

11.00 [4.00, 21.00]

0.019

8.00 [4.00, 18.25]

12.00 [6.00, 26.00]

14.00 [7.00, 28.00]

< 0.001

6.50 [3.00, 13.75]

10.00 [2.00, 14.00]

5.50 [2.00, 11.00]

0.228

36 (16.9%)

31 (14.1%)

43 (20%)

0.260

14.00 [9.00, 22.75]

18.00 [11.00, 28.00]

17.00 [9.50, 29.00]

0.019

15.00 [9.75, 27.25]

20.00 [13.00, 34.00]

23.00 [14.00, 37.00]

< 0.001

10.50 [7.00, 17.75]

14.00 [6.00, 18.00]

9.50 [6.00, 15.00]

0.249

20.00 [13.00, 32.00]

24.00 [15.00, 38.00]

22.00 [12.00, 39.00]

0.076

Survivors

25.00 [16.00, 38.00]

30.00 [20.00, 44.00]

34.00 [21.50, 47.50]

0.001

Non-survivors

10.50 [7.00, 17.75]

15.00 [6.00, 18.00]

9.50 [6.00, 15.00]

0.192

CVVHD Continuous veno-venous hemodiafiltration, CVVH continuous veno-venous hemofiltration, RRTrenal replacement therapy
Data are shown as median [25th percentile, 75th percentile] or N (%). P values in bold text indicate statistical significance at P < 0.05

Fig. 3 Sensitivity analysis showing the consistency of main effect
over ARDS severity. ARDS acute respiratory distress syndrome

increases the extravascular lung water, and inattention
to fluid overload may inadvertently promote counterproductive outcomes, such as pulmonary vascular dysregulation and alveolar edema, contributing to weaning
failure. This risk is particularly high among patients
with COVID-19 and ARDS because of relatively higher
extravascular lung water and pulmonary vascular permeability indices, in distinct contrast to non-COVID ARDS
[23]. Furthermore, alveolar fluid clearance is perhaps
slow or even impaired in ARDS pathophysiology. The
combined processes of high vascular permeability and
impaired alveolar fluid clearance may therefore rapidly
worsen the alveolar edema—even with a slight increase
in intravascular volume [24, 25]. Consistent with this
view, we showed that even a one-liter increase in the dose
of cumulative fluid balance might significantly decrease
ventilation liberation odds. For example, about 14%
(hazard ratio of 0.86) lower rate of successful ventilation

liberation was noted with each liter of fluid addition to
cumulative fluid balance—implying a dose–response
relationship. Importantly, our results do not imply a
causal relationship, as causality can only be identified in
a randomized trial; however, given the strength of association between cumulative fluid balance and weaning
outcome, a well-designed trial seems well justified. Taken
together with the previous research, our results indicate a
possible beneficial effect of restrictive fluid management
in invasively ventilated COVID-19 and ARDS patients.
Higher cumulative fluid balance has also been suggested in previous studies of non-COVID-19 ARDS
patients to be potentially associated with worsened outcomes, such as acute kidney injury and decreased survival [26]. In our study, no association was observed in
the lower cumulative fluid balance group with respect to
our secondary endpoints, such as acute kidney injury, the
requirement of renal replacement therapy, and mortality,
with the caveat that our analysis was too small to evaluate
these endpoints and, therefore, should be considered as
only hypothesis-generating for future investigations.
The strengths of our study include the size of the multicenter cohort of 22 hospitals that comprised both academic and non-academic institutions, increasing the
generalizability of our results. We took careful steps
to prevent selection bias that could have been caused
by patients who were transferred from other hospitals.
Also, trained study coordinators performed careful data
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collection, and a pre-specified statistical analysis plan
was prepared before data acquisition.
Our study is subject to several limitations. Although we
adjusted for a limited set of pre-specified confounders,
our results may be biased by a (large) number of unmeasured confounders. We considered variables observed
after day 0 (such as cumulative vasopressor dose or
ARDS severity on day 4) as potential mediators as they
would presumably be influenced by the cumulative fluid
balance and may be associated with the outcome. Adjusting for these variables would introduce bias through over
adjustment [27, 28]. Our analysis did not account for race
or ethnicity; the possible confounding effects on our primary outcome cannot be determined, therefore limiting
our results’ generalizability and hindering our ability to
examine racial disparity [29]. Significant heterogeneity
exists in the resuscitation paradigm regarding the optimal
time of initiation of diuretics in hemodynamically unstable patients. We acknowledge that the diuretics use, particularly in hemodynamically unstable patients requiring
vasopressors, could be a confounder, not accounted for in
our analysis.
Based on a priori-defined selection criteria, a trivial
fraction (approximately 5%) of patients extubated at
day 3 were excluded from the analysis (Fig. 1). It, therefore, remains unknown whether our findings apply to
patients successfully liberated from invasive ventilation early in the course of the illness. To align with our
pragmatic intent of evaluating the effectiveness of interventions in ‘usual care’ and their operational practicality in the initial months of the COVID-19 pandemic,
dynamic parameters such as cardiac output/index and
other advanced hemodynamic indices were not part of
the a priori-defined collected variables. Multiple challenges to research existed during the pandemic that
may have affected the clinical outcomes for the included
patients, such as organizational issues to utilize resources
to prevent future upheavals. Included data were derived
from 22 collaborative hospitals that exhibited variation
in practice; for example, weaning did not occur with a
mandatory protocol, and healthcare provider-related
bias could have affected the weaning outcomes. While
the percentage of missing values was low, missing datarelated bias due to the adoption of different severity illness scores by various centers was thoroughly handled by
imputation approaches such as last observation carried
forward and robust evaluation tools.

Conclusions
This multicenter study of invasively ventilated COVID19 and ARDS patients suggests a strong association
between higher day 3 cumulative fluid balance and the
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duration of ventilation, even after adjusting for a predefined set of possible confounding variables. Nevertheless, randomized clinical trials are required to confirm
our findings. To the extent that higher positive fluid balance suggests harm and influences weaning outcomes,
maintenance of restrictive cumulative fluid balance
may improve weaning outcomes in invasively ventilated
COVID-19 and ARDS patients.
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